BlossomHill Therapeutics (BLSM) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($555.6 million vs $533.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | DRUG |
|---|---|---|
| Share price | $17.48 | $54.05 |
| Market cap | $555.60M | $533.15M |
| 1-day change | +3.55% | +3.94% |
| YTD return | — | -30.74% |
| 1-year return | — | -11.99% |
| 5-year return | — | +45.49% |
| EPS (TTM) | $-4.83 | $-2.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $123.75 |
| 52-week low | $15.25 | $47.23 |
| Distance from 52-week high | -37.55% | -56.32% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +102.52% | +181.17% |
| Average volume | 261.23K | 156.28K |
| Shares outstanding | 31.78M | 9.86M |
| Employees | 69 | 26 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: BlossomHill Therapeutics in Healthcare and Bright Minds Biosciences in Health Care.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Healthcare · Biotechnology · 69 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
BLSM vs DRUG FAQ
Which is bigger, BlossomHill Therapeutics or Bright Minds Biosciences?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $555.60M compared with $533.15M for Bright Minds Biosciences (DRUG).
Are BlossomHill Therapeutics and Bright Minds Biosciences in the same industry?
No. BlossomHill Therapeutics is in the Healthcare sector, while Bright Minds Biosciences is in Health Care.